<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114156">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01711567</url>
  </required_header>
  <id_info>
    <org_study_id>STEEP study</org_study_id>
    <nct_id>NCT01711567</nct_id>
  </id_info>
  <brief_title>Switching to Tenofovir Versus Continuing Entecavir in Chronic Hepatitis B Patients With Partial Virologic Response During Entecavir Therapy: STEEP Study</brief_title>
  <acronym>STEEP</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Entecavir, a potent antiviral agent, has been widely used for treatment-naïve chronic
      hepatitis B patients. However,  about 20% of  patients showed  partial virologic response
      after 2 year of entecavir therapy (33% in HBeAg positive, 10% in HBeAg negative patients).
      Tenofovir  is a nucleotide analogue with more potent antiviral activity. In addition, there
      is no cross resistance between the two drugs. Therefore it is assumed that tenofovir would
      be effective in the treatment of chronic hepatitis B patients who shows partial virologic
      response (detectable HBV DNA by real time PCR after 12 months of treatment) despite
      treatment with entecavir.  In this study, we will compare the efficacy of switching to
      tenofovir with continuing entecavir in patients who shows partial virologic response to
      entecavir.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Virologic response rate at year 1 (12 months) (HBV DNA &lt; 20 IU/mL)</measure>
    <time_frame>up to the end of year 1 (12 months)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>-Degree of HBV DNA reduction, mean HBV DNA, biochemical and serologic response rates, resistance, and adverse events at year 1</measure>
    <time_frame>up to the end of year 1 (12 months)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>entecavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard drugs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tenofovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>study drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir</intervention_name>
    <description>tenofovir 300 mg qd</description>
    <arm_group_label>tenofovir</arm_group_label>
    <other_name>tenofovir (viread)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>entecavir</intervention_name>
    <description>entecavir 0.5 mg qd</description>
    <arm_group_label>entecavir</arm_group_label>
    <other_name>entecavir(baraclude) 0.5 mg qd</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. CHB patients (positive HBsAg more than 6 months)

          2. Age 19 years old

          3. HBeAg positive or negative patients

          4. Patients receiving entecavir 0.5 mg more than 12 months

          5. Detectable HBV DNA by real time PCR (HBV &gt; 60 IU/mL)

          6. Compensated liver function (Child-Pugh-Turcotte score ≤7, prothrombin time 3 sec
             above ULN or INR ≤1.5, serum albumin &gt;3 g/dL, total bilirubin &lt;2.5 mg/dL, no history
             of variceal bleeding, diuretics or ascites requiring paracentesis, hepatic
             encephalopathy)

        Exclusion Criteria:

          1. History of treatment with nucleotide analogue

          2. Detectable entecavir resistant mutation by RFMP

          3. Decompensated cirrhosis (CTP score &gt;7)

          4. Patients with HCC

          5. Seropositivity to HCV, HDV or HIV

          6. Pregnant and lactating woman
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyung Joon Yim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyung Joon Yim, M.D.</last_name>
    <phone>82-31-412-5583</phone>
    <email>gudwns21@medimail.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sang Jun Suh, M.D.</last_name>
    <phone>82-31-412-4926</phone>
    <email>mothpickle@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <state>Gyeonggi-do</state>
        <zip>425-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyung Joon Yim, M.D.</last_name>
      <phone>82-31-412-5583</phone>
      <email>gudwns21@medimail.co.kr</email>
    </contact>
    <contact_backup>
      <last_name>Sang Jun Suh, M.D.</last_name>
      <phone>82-31-412-4926</phone>
      <email>mothpickle@naver.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hyung Joon Yim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 26, 2014</lastchanged_date>
  <firstreceived_date>October 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University</investigator_affiliation>
    <investigator_full_name>Hyung Joon Yim</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Chronic Hepatitis B</keyword>
  <keyword>TENOFOVIR</keyword>
  <keyword>ENTECAVIR</keyword>
  <keyword>PARTIAL RESPONDER</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Tenofovir disoproxil</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
